Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379340658> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4379340658 endingPage "TPS10073" @default.
- W4379340658 startingPage "TPS10073" @default.
- W4379340658 abstract "TPS10073 Background: Intravenous irinotecan hydrochloride (IRN-IV) is approved for the treatment of adult colorectal cancer and also used off-label to treat a range of adult and pediatric tumors including recurrent Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, Wilms tumor, gynecologic cancers, lung cancer and medulloblastoma. Previously, a regimen of IRN-IV administered as a 60-min i.v. infusion daily for 5 days, bi-weekly in combination with other agents such as temozolomide has been recommended use in treating children with solid tumors (Blaney. ClinCanRes, 2001). Protracted administration schedule of IRN-IV is inconvenient for patients, so oral regimens utilizing IRN-IV have been developed and implemented with favorable tumor response (Wagner. ClinSarcRes, 2015). Unfortunately, the palatability of the IRN-IV is poor, leading to reduced compliance especially in younger pediatric patients. Development of an advanced formulation to improve tolerability and patient compliance is an important unmet need. VAL-413 is a novel formulation developed to improve palatability of oral irinotecan. This pilot trial will examine the safety and tolerability of this novel formulation and assess pharmacokinetics compared to current oral regimen. Methods: Eligibility: Up to 20 patients ≥ 1 year of age or ≤ 30 years of age with recurrent pediatric solid tumors and adequate bone marrow, renal and liver function, for whom irinotecan therapy is a treatment option will be enrolled. Trial Design: Two different dose levels of VAL-413, 90mg/m2/day or 110mg/m2/day will be studied in combination with fixed-dose temozolomide using a standard 3 + 3 phase I design. In the event the starting dose of 90 mg/m2/day is not tolerable due to toxicity, a lower dose of 75 mg/m2/day may be implemented. Treatment: During the first cycle of treatment, each patient will receive 4 daily doses of VAL-413 and one daily dose of the intravenous preparation of irinotecan taken orally (IRN-IVPO). During all subsequent cycles, only VAL-413 will be given with temozolomide in 5-day courses administered every 21 days, as tolerated. Outcome Measures:Toxicity is assessed by NCI CCTCAEv5; tumor response is assessed by RECIST 1.1. A palatability survey instrument will assess palatability of VAL-413 vs. IRN-IVPO; comparative intra-patient pharmacokinetics of irinotecan and its metabolites will be assessed. This trial is ongoing (CT.gov: NCT04337177), with no DLT observed to date. Clinical trial information: NCT04337177 ." @default.
- W4379340658 created "2023-06-05" @default.
- W4379340658 creator A5006358327 @default.
- W4379340658 creator A5008062466 @default.
- W4379340658 creator A5014794937 @default.
- W4379340658 creator A5024860663 @default.
- W4379340658 creator A5046497194 @default.
- W4379340658 creator A5050440486 @default.
- W4379340658 creator A5058782198 @default.
- W4379340658 creator A5066731966 @default.
- W4379340658 creator A5074724246 @default.
- W4379340658 creator A5087672907 @default.
- W4379340658 creator A5091035596 @default.
- W4379340658 date "2023-06-01" @default.
- W4379340658 modified "2023-09-25" @default.
- W4379340658 title "A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors." @default.
- W4379340658 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.tps10073" @default.
- W4379340658 hasPublicationYear "2023" @default.
- W4379340658 type Work @default.
- W4379340658 citedByCount "0" @default.
- W4379340658 crossrefType "journal-article" @default.
- W4379340658 hasAuthorship W4379340658A5006358327 @default.
- W4379340658 hasAuthorship W4379340658A5008062466 @default.
- W4379340658 hasAuthorship W4379340658A5014794937 @default.
- W4379340658 hasAuthorship W4379340658A5024860663 @default.
- W4379340658 hasAuthorship W4379340658A5046497194 @default.
- W4379340658 hasAuthorship W4379340658A5050440486 @default.
- W4379340658 hasAuthorship W4379340658A5058782198 @default.
- W4379340658 hasAuthorship W4379340658A5066731966 @default.
- W4379340658 hasAuthorship W4379340658A5074724246 @default.
- W4379340658 hasAuthorship W4379340658A5087672907 @default.
- W4379340658 hasAuthorship W4379340658A5091035596 @default.
- W4379340658 hasConcept C121608353 @default.
- W4379340658 hasConcept C126322002 @default.
- W4379340658 hasConcept C141071460 @default.
- W4379340658 hasConcept C142724271 @default.
- W4379340658 hasConcept C143998085 @default.
- W4379340658 hasConcept C197934379 @default.
- W4379340658 hasConcept C2776581026 @default.
- W4379340658 hasConcept C2776694085 @default.
- W4379340658 hasConcept C2777389519 @default.
- W4379340658 hasConcept C2778256501 @default.
- W4379340658 hasConcept C2778375690 @default.
- W4379340658 hasConcept C2780259306 @default.
- W4379340658 hasConcept C2780844630 @default.
- W4379340658 hasConcept C2781413609 @default.
- W4379340658 hasConcept C526805850 @default.
- W4379340658 hasConcept C71924100 @default.
- W4379340658 hasConceptScore W4379340658C121608353 @default.
- W4379340658 hasConceptScore W4379340658C126322002 @default.
- W4379340658 hasConceptScore W4379340658C141071460 @default.
- W4379340658 hasConceptScore W4379340658C142724271 @default.
- W4379340658 hasConceptScore W4379340658C143998085 @default.
- W4379340658 hasConceptScore W4379340658C197934379 @default.
- W4379340658 hasConceptScore W4379340658C2776581026 @default.
- W4379340658 hasConceptScore W4379340658C2776694085 @default.
- W4379340658 hasConceptScore W4379340658C2777389519 @default.
- W4379340658 hasConceptScore W4379340658C2778256501 @default.
- W4379340658 hasConceptScore W4379340658C2778375690 @default.
- W4379340658 hasConceptScore W4379340658C2780259306 @default.
- W4379340658 hasConceptScore W4379340658C2780844630 @default.
- W4379340658 hasConceptScore W4379340658C2781413609 @default.
- W4379340658 hasConceptScore W4379340658C526805850 @default.
- W4379340658 hasConceptScore W4379340658C71924100 @default.
- W4379340658 hasIssue "16_suppl" @default.
- W4379340658 hasLocation W43793406581 @default.
- W4379340658 hasOpenAccess W4379340658 @default.
- W4379340658 hasPrimaryLocation W43793406581 @default.
- W4379340658 hasRelatedWork W1970193197 @default.
- W4379340658 hasRelatedWork W2049104010 @default.
- W4379340658 hasRelatedWork W2149228256 @default.
- W4379340658 hasRelatedWork W2234353674 @default.
- W4379340658 hasRelatedWork W2262819074 @default.
- W4379340658 hasRelatedWork W3082107997 @default.
- W4379340658 hasRelatedWork W3160665980 @default.
- W4379340658 hasRelatedWork W3165905272 @default.
- W4379340658 hasRelatedWork W4288051129 @default.
- W4379340658 hasRelatedWork W4365512360 @default.
- W4379340658 hasVolume "41" @default.
- W4379340658 isParatext "false" @default.
- W4379340658 isRetracted "false" @default.
- W4379340658 workType "article" @default.